Genolution

Genolution Inventory/Revenue

The Inventory to Revenue Ratio of Genolution (225220.KQ) as of Oct 29, 2026 is 33.79 %. In the previous year, Inventory to Revenue Ratio was 28.68 % — a change of 17.84% (higher).

Inventory/Revenue

33.79 %

YoY

17.84%

Last updated:

Inventory to Revenue Ratio of Genolution is 2025 33.79 % . Inventory to Revenue Ratio of Genolution was 2024 28.68 % . It decreases by 17.84% higher compared to the previous year.

The Genolution Inventory/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory/Revenue
Date
Inventory/Revenue
Jan 1, 2018
8.15 KRW
Jan 1, 2019
14.75 KRW
Jan 1, 2020
3.65 KRW
Jan 1, 2021
2.37 KRW
Jan 1, 2022
10.62 KRW
Jan 1, 2023
20.05 KRW
Jan 1, 2024
28.68 KRW
Jan 1, 2025
33.79 KRW
The Genolution Inventory/Revenue history
YEARInventory/RevenueYoY
33.79 %+17.84%
28.68 %+43.02%
20.05 %+88.82%
10.62 %+347.97%
2.37 %-35.01%
3.65 %-75.28%
14.75 %+81.10%
8.15 %+52.51%
5.34 %-61.89%
14.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Inventory to Revenue Ratio of Genolution is 33.79 % in 2025.

Inventory to Revenue Ratio of Genolution changed from 28.68 % to 33.79 %, representing a 17.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory to Revenue Ratio Genolution since 2006 – with annual values, charts, and detailed analysis.

The Inventory/Revenue ratio shows what percentage of revenue is held as inventory. Rising ratios may indicate slowing demand or inventory management issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory to Revenue Ratio's Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genolution

All Key Metrics — Genolution